Adial Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Adial Pharmaceuticals, Inc. (ADIL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.00 per share for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-08.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-05-08
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $16.75, a 1369.30% increase year-over-year.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $1.14.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $1.63.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $16.70, a 35.55% decline from fiscal 2024.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $25.91, a 324.06% increase from fiscal 2023.
- Adial Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $6.11.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | $0.00 10-Q · filed 2026-05-08 | ||||||
| 2025-12-31 | $16.70 10-K · filed 2026-03-05 | ||||||
| 2025-09-30 | $0.59 10-Q · filed 2025-11-13 | ||||||
| 2025-06-30 | $0.59 10-Q · filed 2025-08-13 | ||||||
| 2025-03-31 | $16.75 10-Q · filed 2026-05-08 | $0.67 10-Q · filed 2025-05-14 | |||||
| 2024-12-31 | $1.04 10-K · filed 2025-03-04 | $25.91 10-K · filed 2026-03-05 | |||||
| 2024-09-30 | $1.14 10-Q · filed 2025-11-13 | ||||||
| 2024-06-30 | $1.14 10-Q · filed 2025-08-13 | $2.07 10-Q · filed 2024-08-13 | |||||
| 2024-03-31 | $1.14 10-Q · filed 2025-05-14 | ||||||
| 2023-12-31 | $6.11 10-K · filed 2025-03-04 | ||||||
| 2022-09-30 | $1.74 10-Q · filed 2022-11-14 | ||||||
| 2022-06-30 | $1.59 10-Q · filed 2022-08-15 | ||||||
| 2022-03-31 | $1.63 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |